You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

Article info

Article menu
XML
Oncolytic and local immunotherapy
Original research
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

Authors

  • Takaaki Oba Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADivision of Breast and Endocrine Surgery, Department of Surgery, Shinshu University, Matsumoto, Nagano, Japan PubMed articlesGoogle scholar articles
  • Kenichi Makino Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADepartment of Obstetrics and Gynecology, Akita University Graduate School of Medicine, Akita, Japan PubMed articlesGoogle scholar articles
  • Ryutaro Kajihara Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA PubMed articlesGoogle scholar articles
  • Toshihiro Yokoi Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA PubMed articlesGoogle scholar articles
  • Ryoko Araki Department of Basic Medical Sciences for Radiation Damages, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan PubMed articlesGoogle scholar articles
  • Masumi Abe Department of Basic Medical Sciences for Radiation Damages, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan PubMed articlesGoogle scholar articles
  • Hans Minderman Flow & Image Cytometry Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA PubMed articlesGoogle scholar articles
  • Alfred E Chang Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • Kunle Odunsi Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USAUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Fumito Ito Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADepartment of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, Nuew York, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Fumito Ito; fumito.ito{at}roswellpark.org
View Full Text

Citation

Oba T, Makino K, Kajihara R, et al
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
Journal for ImmunoTherapy of Cancer 2021;9:e002432. doi: 10.1136/jitc-2021-002432

Publication history

  • Accepted April 23, 2021
  • First published May 28, 2021.
Online issue publication 
February 07, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.